Therapeutic strategies for HER2-positive breast cancer with central ...
With the recognition of T-DXd as the preferred second-line treatment regimen of HER2-positive ABC, and with ongoing clinical trials investigating its role ...
Management of patients with HER2-positive metastatic breast ...Risk factors for CHF: low LVEF, age, obesity, hypertension. ? LVEF is mandatory before initiation of trastuzumab and during treatment. ESO-ESMO EEBR Masterclass ... Real-world treatment patterns and outcomes of patients with HER2+ ...Eligible studies were randomised controlled trials (RCTs) that compared a treatment duration of 6 months or less (?6 months) of trastuzumab or ... MANAGEMENT OF HER2-POSITIVE BREAST CANCERThis study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with.
Autres Cours:
